Despite that we did not find differences in IL-6 among NSCLC patients classified according to anti-PD-(L)1 response, in other cancers, such as melanoma and breast cancer, IL-6 levels at baseline have been correlated with rapid disease progression [44,45]. This evidence concerns the gene IL6 and non-small cell lung carcinoma.